Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* if women of child-bearing potential, have a negative urine pregnancy test~* Willing to use only a non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study~* Male or female, 12-45 years of age with body weight between 52 and 88 kg~* Diagnosis of acne vulgaris with:~  20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones)~* No more than 2 nodules on the face~* Investigator's Global Assessment (IGA) score of moderate (3) to severe (4)~Exclusion Criteria:~* Dermatological condition of face or facial hair that could interfere with clinical evaluations subjects who have used the following medications (topical refers only to the facial area) will not be eligible:~Within 1 week prior to randomization:~* Medicated facial cleansers~* Topical acne treatments (other than those listed below)~Within 4 weeks prior to randomization:~* Topical retinoids~* Topical anti-inflammatories and corticosteroids~* Systemic antibiotics~* Systemic acne treatments~Within 12 weeks prior to randomization:~* Systemic retinoids~* Systemic corticosteroids~* Pseudomembranous colitis or antibiotic-associated colitis~* Hepatitis, liver damage or renal impairment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- P005672-HCl approximately 0.75 mg/kg/day (Type: EXPERIMENTAL): One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
- P005672-HCl approximately 1.5 mg/kg/day (Type: EXPERIMENTAL): Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
- P005672-HCl approximately 3.0 mg/kg/day (Type: EXPERIMENTAL): Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).